Moleculin Files with FDA for Expedited Approval Pathway for Annamycin
HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical […]
Files
HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical […]Files
Moleculin Files with FDA for Expedited Approval Pathway for Annamycin
Copyright © 2024